Objective: To evaluate the safety of intracoronary (IC) abciximab during percutaneous coronary intervention (PCI). Background: Adjunctive treatment with glycoprotein IIb/IIIa inhibitors, especially abciximab, during PCI has been shown to improve clinical and procedural outcomes in numerous studies. However, significant bleeding complications exist with its use and this has limited its standard use. Interest has grown in local (IC) use with studies showing safety and long-term effectiveness, especially in patients with high thrombus loads. Methods: A retrospective review of records in a database of patients who had PCI by a single operator at the Easton Hospital. Results: 611 patients received IC abciximab, and there were no complications in 610 (98.3%) patients; only 1 had an allergic reaction. Conclusions: IC abciximab is safe and has a unique role in the catheterization lab and in patients at high risk of bleeding complications who would benefit from its limited use.
Gibson CMPrimary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. Ann Intern Med. 1999;130:841-847.
2.
Antoniucci D. , Migliorini A., Parodi G., et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation. 2004;109:1704-1706.
3.
Antoniucci D. , Rodriguez A., Hempel A., et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction . J Am Coll Cardiol. 2003;42:1879-1885.
4.
Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001; 344:1895-1903.
5.
The EPIC Investigators.Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
6.
Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation. 1999;99:1951-1958.
7.
Islam MA, Blankenship JC, Balog C., et al. EPISTENT investigators. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). Am J Cardiol . 2002;90:916-921.
8.
Romagnoli E. , Burzotta F., Trani C., et al. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis. 2007;23:57-63.
9.
Wohrle J., Grebe OC, Nusser T., et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty . Circulation. 2003;107: 1840-1843.
10.
Romagnoli E. , Burzotta F., Trani C., et al. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI . Int J Cardiol. 2005; 105:250-255.
11.
Kakkar AK, Moustapha A., Hanley HG, et al. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv . 2004;61: 31-34.
12.
Bellandi F., Maioli M., Gallopin M., et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv. 2004;62:186-192.
13.
Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006; 113:e166-e286.
14.
Aymong ED, Curtis MJ, Youssef M., et al. Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. Circulation. 2002 ;105:2981-2985.
15.
Marciniak SJ Jr, Mascelli MA, Furman MI, et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002;87:1020-1025.
16.
Kleiman NS, Raizner AE, Jordan R., et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol. 1995;26:1665-1671.
17.
Batchelor WB , Tolleson TR, Huang Y., et al. Randomized COMparison of platelet inhibition with Abciximab, TiRofiban and Eptifibatide during PCI in ACS. The COMPARE trial. Circulation. 2002;106:1470-1476.
18.
Marzilli M. , Sambuceti G., Testa R., Fedele S.Platelet glycoprotein IIB/IIIa receptor blockade and coronary resistance in unstable angina. J Am Coll Cardiol . 2002;40:2102-2109.
19.
Collet JP, Montalescot G., Lesty C., et al. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention . Circulation. 2001;103:2328-2331.
20.
Collet JP, Montalescot G., Lesty C., et al. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol. 2001;21:142-148.
21.
Sharma S., Makkar R., Lardizabal J.Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach? J Cardiovasc Pharmacol Ther. 2006;11:136-141.
22.
Waldmann TA , Levy R., Coller BSEmerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. Hematology Am Soc Hematol Educ Program. 2000:394-408.
23.
Barsness GW , Buller C., Ohman EM, et al. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts . Am Heart J. 2000;139:824-829.
24.
Lee CH, Ho KT, Tan HCInstant dissolution of intracoronary thrombus by abciximab. Int J Cardiol. 2005;104:102-103.
25.
Muhlestein JB, Karagounis LA, Treehan S., Anderson JL "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol.1997;30:1729-1734.
26.
Alexander KP , Chen AY, Newby LK, et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation. 2006;114:1380-1387.
27.
Sadeghi HM, Grines CL, Chandra HR, et al. Percutaneous coronary interventions in octogenarians: glycoprotein IIb/IIIa receptor inhibitors' safety profile. J Am Coll Cardiol . 2003;42:428-432.
28.
Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade: the EPISTENT investigators.Evaluation of Platelet IIb/IIIa inhibitor for stenting. Lancet . 1998;352:87-92.
29.
Guagliumi G. , Stone GW, Cox DA, et al. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2004;110:1598-1604.
30.
The EPILOG investigators.Platelet glycoprotein IIb/IIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997; 336:1689-1696.
31.
Cote AV, Berger PB, Holmes DR Jr, et al. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. Mayo Clin Proc. 2001;76:890-896.
32.
Stone GW, Bertrand ME, Moses JW, et al; ACUITY Investigators.Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA . 2007;297:591-602.
33.
Mehta RH, Harjai KH, Grines L., et al. Sustained ventricular tachycardia or fibrillation in the cardiac catheterization laboratory among patients receiving primary percutaneous coronary intervention: incidence, predictors, and outcomes. Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. J Am Coll Cardiol . 2004;43: 1765-1772.
